Cerebral Palsy and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains
The ClinicalTrials.gov registry holds 8 records for HSCT in Cerebral Palsy: 0 recruiting now, 1 labelled Phase 3 or 4, across 4 countries. Snapshot 2026-08-29.
Why this is studied in Cerebral Palsy
Cerebral palsy follows a fixed early brain injury; the injury does not progress, but its functional consequences change as a child grows. Cell therapy is studied for neuroplasticity support alongside intensive rehabilitation. Because rehabilitation itself drives measurable gains, separating a cell effect from a therapy effect is the central design problem, and commercial offers almost never try.
What HSCT means in this table
Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.
The numbers
Every figure below comes from one reproducible query (cerebral palsy x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 8 |
| Interventional studies in the sample | 8 |
| Recruiting right now | 0 |
| Completed | 6 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 1 |
| Countries with at least one site | 4 |
| Median planned enrolment | 35 participants |
| Largest single planned enrolment | 300 participants |
| First / most recent start year | 2011 — 2016 |
How mature is this evidence?
Only 1 of 8 registrations reached a confirmatory phase label, so most of what a clinic can cite is exploratory work by design.
6 records are marked completed and 0 ended early (terminated, withdrawn or suspended): 0% of registrations did not run to plan.
| Phase label | Records | Share |
|---|---|---|
| Phase 2 | 6 | 60% |
| Phase 1 | 3 | 30% |
| Phase 3 | 1 | 10% |
Median planned enrolment is 35 participants (largest single study: 300). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Research is not evenly spread: Vietnam carries about 43% of the country mentions among 4 countries with sites.
| Country | Studies with a site there |
|---|---|
| Vietnam | 3 |
| Iran | 2 |
| China | 1 |
| Mexico | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
Sponsorship leans academic: 5 of the most frequent lead sponsors read as academic or hospital entities and 3 as companies. Who pays shapes what gets measured and what gets published.
- Royan Institute — 2 records
- Vinmec Healthcare System — 2 records
- General Hospital of Chinese Armed Police Forces — 1 record
- Hospital Universitario Dr. Jose E. Gonzalez — 1 record
- Vinmec Research Institute of Stem Cell and Gene Technology — 1 record
- Stem Cells Arabia — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT01929434 — Efficacy of Stem Cell Transplantation Compared to Rehabilitation Treatment of Patients With Cerebral Paralysis | Phase 3 | Completed | 300 | General Hospital of Chinese Armed Police Forces | 2013-10 |
| NCT03078621 — Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy | Phase 1, Phase 2 | Unknown | 50 | Stem Cells Arabia | 2016-09 |
| NCT02574923 — Outcomes of Stem Cells for Cerebral Palsy | Phase 2 | Completed | 30 | Vinmec Healthcare System | 2015-11-05 |
| NCT03123562 — Improvement in Gross Motor Function and Muscle Tone in Children With Cerebral Palsy Related to Neonatal Icterus | Phase 2 | Completed | 25 | Vinmec Research Institute of Stem Cell and Gene Technology | 2014-04-01 |
| NCT02569775 — Outcomes of Stem Cells for Cerebral Palsy | Phase 2 | Completed | 40 | Vinmec Healthcare System | 2014-04 |
| NCT02231242 — Intrathecal Stem Cells for Cerebral Palsy Phase II | Phase 2 | Unknown | 60 | Hospital Universitario Dr. Jose E. Gonzalez | 2013-09 |
| NCT01763255 — Multiple Transplantation of Bone Marrow Derived CD133 Cell in Cerebral Palsy | Phase 1, Phase 2 | Completed | 8 | Royan Institute | 2012-04 |
| NCT01404663 — Side Effects of Bone Marrow Derived CD133 Transplantation in Cerebral Palsy | Phase 1 | Completed | 12 | Royan Institute | 2011-10 |
What this page does and does not tell you
These figures describe effort, not outcome. Published results, with their control arms and endpoints, are where benefit is decided.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many HSCT studies for Cerebral Palsy are recruiting right now?
0 of 8 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is HSCT an approved treatment for Cerebral Palsy?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 8 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on HSCT for Cerebral Palsy?
1 of 8 records carry a Phase 3 or Phase 4 label and 6 are marked completed. Registrations run from 2011 to 2016.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.